Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to $278130.0.

  • Kymera Therapeutics' Gains from Sales and Divestitures rose 6483.63% to $278130.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $278130.0, marking a year-over-year increase of 6483.63%. This contributed to the annual value of $174463.0 for FY2024, which is 34155.55% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Gains from Sales and Divestitures stood at $278130.0, which was up 6483.63% from $224882.0 recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Gains from Sales and Divestitures ranged from a high of $278130.0 in Q3 2025 and a low of $14215.0 during Q1 2022
  • Over the past 5 years, Kymera Therapeutics' median Gains from Sales and Divestitures value was $39511.0 (recorded in 2023), while the average stood at $88882.8.
  • As far as peak fluctuations go, Kymera Therapeutics' Gains from Sales and Divestitures crashed by 5655.62% in 2022, and later surged by 37147.34% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $84859.0 in 2021, then plummeted by 56.56% to $36866.0 in 2022, then increased by 7.17% to $39511.0 in 2023, then surged by 341.56% to $174463.0 in 2024, then skyrocketed by 59.42% to $278130.0 in 2025.
  • Its Gains from Sales and Divestitures was $278130.0 in Q3 2025, compared to $224882.0 in Q2 2025 and $146869.0 in Q1 2025.